Supplements for Fertility Support

A placental glycoprotein hormone that acts as a long-acting LH analogue: it binds the LH/CG receptor on testicular Leydig cells (and ovarian theca cells) to drive sex-steroid production. Honest appraisal: it is genuinely well-established for inducing ovulation/the final-maturation 'trigger' in female fertility, for inducing spermatogenesis in men with hypogonadotropic hypogonadism, and for maintaining intratesticular testosterone and sperm production in men on testosterone therapy who want to preserve fertility. Its proven benefits are confined to the gonadal axis — it does not improve systemic longevity or healthspan, and grey-market/compounded sourcing carries real risks.

A synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.

A hypothalamic neuropeptide (from the KISS1 gene) that sits at the top of the reproductive hormone axis — it stimulates GnRH neurons to release LH and FSH. It has a genuinely rigorous human-research record, largely from the Dhillo group at Imperial College London: kisspeptin-54 has been tested as an IVF egg-maturation trigger, in hypothalamic amenorrhea, and for sexual/emotional brain processing. Honest framing: this is legitimate investigational science, NOT an approved drug or a dietary supplement, and the grey-market 'libido peptide' sold online is not the supervised clinical product.

A racemic selective estrogen receptor modulator (SERM) that has been FDA-approved for decades for female ovulation induction, and is used off-label in men with secondary (low-LH) hypogonadism to raise endogenous testosterone while preserving fertility. By blocking estrogen feedback at the hypothalamus it increases LH and FSH, driving the testes to make more testosterone — unlike testosterone gels/injections, which suppress both. Honest appraisal: clomiphene is the RACEMIC mixture of enclomiphene (trans, the active estrogen-antagonist isomer) and zuclomiphene (cis, a long-lived weakly estrogenic isomer that accumulates) — the zuclomiphene downside is the entire reason the single-isomer enclomiphene was developed. Male use is off-label, the evidence is mostly observational and surrogate-based (testosterone/LH/FSH), and there are NO long-term hard-outcome trials. It is NOT a longevity drug.

The trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used off-label/investigationally as a 'fertility-sparing' testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone while preserving sperm production, unlike exogenous testosterone, which suppresses both. Honest appraisal: Phase-2/3 RCTs show it raises testosterone and keeps sperm counts in the normal range vs topical testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded/off-label, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality).

A potent non-steroidal aromatase inhibitor (Femara) that blocks estrogen synthesis. Approved for hormone-receptor-positive breast cancer, it is also the evidence-backed first-line drug for ovulation induction in PCOS — where a landmark NEJM RCT showed it BEAT clomiphene on live births. Used off-label in men to raise testosterone and lower estradiol, but that estrogen suppression harms bone and lipids, and in growing boys it carries a vertebral-deformity signal. A prescription drug, not a supplement, and NOT a longevity drug.

The endogenous steroid hormone, sold as a prescription bioidentical (micronized) drug (Prometrium / Utrogestan). It is the essential ENDOMETRIAL-PROTECTION half of menopausal hormone therapy — it opposes estrogen to prevent endometrial hyperplasia/cancer — and is used for luteal support in IVF and to treat secondary amenorrhea. Oral micronized progesterone is also widely used OFF-LABEL for menopausal SLEEP and hot flashes, because a metabolite (allopregnanolone) is GABA-active and sedating. Randomized trials support these specific indications; in early-pregnancy bleeding (PRISM) benefit was limited to women with prior miscarriages. It is NOT a general healthy-population enhancer, and the breast-cancer signal from older synthetic progestins (WHI) should not be assumed for micronized progesterone, where data suggest it is more breast- and metabolically neutral but longer-term evidence is limited. Prescription-only and NOT a dietary supplement; OTC 'progesterone creams' absorb erratically and are not equivalent.

A selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug.